Mesoblast (MESO) Revenue (2014 - 2023)
Mesoblast (MESO) posted Revenue of $1.9 million for Q2 2023, down 4.33% sequentially from $1.9 million in Q1 2023, and down 17.26% YoY from $2.2 million in Q2 2022.
Mesoblast (MESO) Revenue (2014 - 2023) Analysis & Trends
Mesoblast has reported Revenue for 10 years, with the latest figure at $1.9 million in Q2 2023.
- Quarterly Revenue fell 17.26% year-over-year to $1.9 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $8.1 million (down 20.21% YoY) and the FY2025 annual result came in at $17.2 million, up 191.39% from the prior year.
- Revenue retreated to $1.9 million in Q2 2023 per MESO's latest filing, from $1.9 million in the prior quarter.
- Over five years, Revenue peaked at $26.2 million in Q2 2020 and troughed at $1.0 million in Q1 2019.
- A 5-year average of $3.4 million and a median of $2.0 million in 2021 frame the typical range for Revenue.
- The sharpest annual moves came in 2020 and 2021: Revenue jumped 1233.71% in 2020, then plunged 92.39% in 2021.
- Over 5 years, Revenue stood at $2.0 million in 2019, then climbed by 13.81% to $2.2 million in 2020, then surged by 57.79% to $3.5 million in 2021, then plunged by 39.65% to $2.1 million in 2022, then dropped by 13.07% to $1.9 million in 2023.
- According to Business Quant data, Revenue over the past three periods registered $1.9 million, $1.9 million, and $2.1 million for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Mesoblast | 2.01 Bn | 1.87 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 1.86 Mn |
| Mar 31, 2023 | 1.94 Mn |
| Dec 31, 2022 | 2.13 Mn |
| Sep 30, 2022 | 2.22 Mn |
| Jun 30, 2022 | 2.24 Mn |
| Mar 31, 2022 | 2.01 Mn |
| Dec 31, 2021 | 3.54 Mn |
| Sep 30, 2021 | 2.42 Mn |
| Jun 30, 2021 | 2.00 Mn |
| Mar 31, 2021 | 1.96 Mn |
| Dec 31, 2020 | 2.24 Mn |
| Sep 30, 2020 | 1.31 Mn |
| Jun 30, 2020 | 26.23 Mn |
| Mar 31, 2020 | 2.08 Mn |
| Dec 31, 2019 | 1.97 Mn |
| Sep 30, 2019 | 1.87 Mn |
| Jun 30, 2019 | 1.97 Mn |
| Mar 31, 2019 | 1.04 Mn |
| Dec 31, 2018 | 1.22 Mn |
| Sep 30, 2018 | 1.10 Mn |